Faron, etusivu

releases and publications

Faron announces new data that highlight patient populations with cancer that are most likely to benefit from first-in-class immunotherapy bexmarilimab

Faron Appoints Ralph Hughes as Chief Business Officer (CBO)

Regulatory

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress

Faron Pharmaceuticals Ltd: Grant of Options

Insider Transaction Regulatory

Faron Pharmaceuticals presents promising Phase 1/2 data from BEXMAB Study at MDS 2025 plenary session

Faron announces acceptance of bexmarilimab Phase II data for oral presentation at ASCO 2025

Holding in Company

Regulatory

Inside Information: Faron Announces Positive Phase II results in higher-risk myelodysplastic syndrome

Regulatory

Inside Information: Faron enters into an up to EUR 35 million convertible bond arrangement and issues first tranche of bonds with a principal amount of EUR 15 million

Regulatory

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at 2025 Annual MDS Foundation Congress

PreviousNext
Back to top